483 related articles for article (PubMed ID: 28081641)
21. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
22. Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers.
Olejarz W; Kubiak-Tomaszewska G; Chrzanowska A; Lorenc T
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823989
[TBL] [Abstract][Full Text] [Related]
23. Targeting tumor vascularization: promising strategies for vascular normalization.
Zheng R; Li F; Li F; Gong A
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2489-2505. PubMed ID: 34148156
[TBL] [Abstract][Full Text] [Related]
24. Vascular endothelial growth factor: biology and therapeutic applications.
Ho QT; Kuo CJ
Int J Biochem Cell Biol; 2007; 39(7-8):1349-57. PubMed ID: 17537667
[TBL] [Abstract][Full Text] [Related]
25. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.
Jain RK
Science; 2005 Jan; 307(5706):58-62. PubMed ID: 15637262
[TBL] [Abstract][Full Text] [Related]
26. Anti-angiogenic alternatives to VEGF blockade.
Khan KA; Bicknell R
Clin Exp Metastasis; 2016 Feb; 33(2):197-210. PubMed ID: 26620208
[TBL] [Abstract][Full Text] [Related]
27. Off-tumor target--beneficial site for antiangiogenic cancer therapy?
Cao Y
Nat Rev Clin Oncol; 2010 Oct; 7(10):604-8. PubMed ID: 20683436
[TBL] [Abstract][Full Text] [Related]
28. Role of the VEGF/VEGFR axis in cancer biology and therapy.
Rapisarda A; Melillo G
Adv Cancer Res; 2012; 114():237-67. PubMed ID: 22588059
[TBL] [Abstract][Full Text] [Related]
29. Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model.
Chauvet N; Romanò N; Lafont C; Guillou A; Galibert E; Bonnefont X; Le Tissier P; Fedele M; Fusco A; Mollard P; Coutry N
Int J Cancer; 2017 May; 140(9):2150-2161. PubMed ID: 28152577
[TBL] [Abstract][Full Text] [Related]
30. sFLT01: a novel fusion protein with antiangiogenic activity.
Bagley RG; Kurtzberg L; Weber W; Nguyen TH; Roth S; Krumbholz R; Yao M; Richards B; Zhang M; Pechan P; Schmid S; Scaria A; Kaplan J; Teicher BA
Mol Cancer Ther; 2011 Mar; 10(3):404-15. PubMed ID: 21252283
[TBL] [Abstract][Full Text] [Related]
31. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
32. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
33. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
34. Tumor angiogenesis and therapy.
Cao Y
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S340-3. PubMed ID: 16507405
[TBL] [Abstract][Full Text] [Related]
35. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan RR; Griffioen AW; Duda DG
Angiogenesis; 2017 May; 20(2):185-204. PubMed ID: 28361267
[TBL] [Abstract][Full Text] [Related]
36. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.
De Bock K; Cauwenberghs S; Carmeliet P
Curr Opin Genet Dev; 2011 Feb; 21(1):73-9. PubMed ID: 21106363
[TBL] [Abstract][Full Text] [Related]
37. Review of selected patents for cancer therapy targeting tumor angiogenesis.
Kirstein MN; Moore MM; Dudek AZ
Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):153-61. PubMed ID: 18221033
[TBL] [Abstract][Full Text] [Related]
38. An updated patent review of VEGFR-2 inhibitors (2017-present).
Farghaly TA; Al-Hasani WA; Abdulwahab HG
Expert Opin Ther Pat; 2021 Nov; 31(11):989-1007. PubMed ID: 34043477
[No Abstract] [Full Text] [Related]
39. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
Tie J; Desai J
Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
[TBL] [Abstract][Full Text] [Related]
40. VEGF as a potential target in lung cancer.
Frezzetti D; Gallo M; Maiello MR; D'Alessio A; Esposito C; Chicchinelli N; Normanno N; De Luca A
Expert Opin Ther Targets; 2017 Oct; 21(10):959-966. PubMed ID: 28831824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
